264,084 Shares in Stevanato Group S.p.A. (NYSE:STVN) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 264,084 shares of the company's stock, valued at approximately $5,754,000. Raymond James Financial Inc. owned approximately 0.09% of Stevanato Group at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. AMI Asset Management Corp acquired a new position in Stevanato Group during the 4th quarter valued at about $1,089,000. SG Americas Securities LLC raised its position in shares of Stevanato Group by 18.2% in the 4th quarter. SG Americas Securities LLC now owns 15,546 shares of the company's stock valued at $339,000 after purchasing an additional 2,389 shares during the last quarter. Jennison Associates LLC purchased a new stake in Stevanato Group during the 4th quarter worth approximately $20,239,000. Conestoga Capital Advisors LLC increased its stake in Stevanato Group by 5.3% during the 4th quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company's stock valued at $176,128,000 after purchasing an additional 407,086 shares in the last quarter. Finally, Truist Financial Corp raised its holdings in shares of Stevanato Group by 4.2% in the fourth quarter. Truist Financial Corp now owns 26,900 shares of the company's stock worth $586,000 after buying an additional 1,073 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. William Blair reissued an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Stephens upgraded Stevanato Group to a "strong-buy" rating in a research note on Monday, April 21st. Finally, UBS Group dropped their target price on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a research report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Stevanato Group currently has a consensus rating of "Moderate Buy" and a consensus price target of €25.70 ($29.20).

Stevanato Group Stock Performance

STVN stock traded down €0.20 ($0.23) during trading on Wednesday, hitting €20.80 ($23.64). 163,300 shares of the company traded hands, compared to its average volume of 340,768. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.82) and a 1 year high of €28.77 ($32.69). The stock's 50-day simple moving average is €20.80 and its 200 day simple moving average is €20.82. The company has a market cap of $6.30 billion, a PE ratio of 44.26, a P/E/G ratio of 7.18 and a beta of 0.52.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of €0.20 ($0.23). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. On average, equities analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.